Acute myeloid leukemia, MLL gene rearrangement
MONDO:0100404Any acute myeloid leukemia that has the chromosomal anomaly MLL gene rearrangement. (A molecular abnormality indicating rearrangement of the MLL (KMT2A) gene.)
Also known as: AML, KMT2A Gene Rearrangement, AML, KMT2A Rearrangement, AML, Lysine (K)-Specific Methyltransferase 2A Gene Rearrangement, AML, Lysine Methyltransferase 2A Gene Rearrangement, AML, MLL Rearrangement, AML, MLL gene rearrangement, AML, Mixed Lineage Leukaemia Gene Rearrangement, AML, Mixed Lineage Leukemia Gene Rearrangement
3114 clinical trials for this condition and its sub-types, 23 tagged with Acute myeloid leukemia, MLL gene rearrangement itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials
Disease control OngoingThis early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…
Phase 1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Promising new combo targets Hard-to-Treat infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Lab-Grown stem cells could speed immune recovery in blood cancer transplants
Disease control OngoingThis phase 2 trial tests whether adding lab-grown umbilical cord blood cells (dilanubicel) to a standard cord blood transplant helps people with blood cancers like leukemia recover their blood and immune cells faster. Participants receive chemotherapy and radiation to prepare the…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for tough leukemia: experimental drug targets genetic flaw
Disease control OngoingThis study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…
Phase 1/2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC